Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes

DEFEND Investigator Group

doi:10.1089/dia.2016.2507

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes

DEFEND Investigator Group

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	S72
Journal	Diabetes Technology and Therapeutics
Volume	18
DOIs	https://doi.org/10.1089/dia.2016.2507
State	Published - Feb 2016

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology
Medical Laboratory Technology

Access to Document

10.1089/dia.2016.2507

Cite this

@article{cc27ac5363c249cb88eaa340da7a2097,

title = "Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes",

author = "{DEFEND Investigator Group} and R. Aronson and Gottlieb, {P. A.} and Christiansen, {J. S.} and Donner, {T. W.} and E. Bosi and Bode, {B. W.} and P. Pozzilli",

year = "2016",

month = feb,

doi = "10.1089/dia.2016.2507",

language = "English (US)",

volume = "18",

pages = "S72",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study

T2 - Results of the randomized phase III study in recent-onset human type 1 diabetes

AU - DEFEND Investigator Group

AU - Aronson, R.

AU - Gottlieb, P. A.

AU - Christiansen, J. S.

AU - Donner, T. W.

AU - Bosi, E.

AU - Bode, B. W.

AU - Pozzilli, P.

PY - 2016/2

Y1 - 2016/2

UR - http://www.scopus.com/inward/record.url?scp=84957670793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957670793&partnerID=8YFLogxK

U2 - 10.1089/dia.2016.2507

DO - 10.1089/dia.2016.2507

M3 - Comment/debate

C2 - 26836431

AN - SCOPUS:84957670793

SN - 1520-9156

VL - 18

SP - S72

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

ER -

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this